[1]张 欣,王 伟,司伟岳,等.1-甲基-4-苯基-1，2，3，6四氢吡啶诱导小鼠嗅觉障碍的实验研究[J].医学信息,2021,34(07):82-84.[doi:10.3969/j.issn.1006-1959.2021.07.022]
　ZHANG Xin,WANG Wei,SI Wei-yue,et al.Experimental study on 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine-induced olfactory dysfunction in mice[J].Medical Information,2021,34(07):82-84.[doi:10.3969/j.issn.1006-1959.2021.07.022]
点击复制

1-甲基-4-苯基-1，2，3，6四氢吡啶诱导小鼠嗅觉障碍的实验研究()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年07期
页码:
82-84
栏目:
论著
出版日期:
2021-04-01

文章信息/Info

Title:
Experimental study on 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine-induced olfactory dysfunction in mice
文章编号:
1006-1959（2021）07-0082-03
作者:
张 欣; 王 伟; 司伟岳; 等
（1.山东第一医科大学/山东省医学科学院基础医学院，山东 泰安 271000； 2.泰安市第一人民医院神经内科，山东 泰安 271000）
Author(s):
ZHANG Xin; WANG Wei; SI Wei-yue; et al.
(1.School of Basic Medical Sciences,Shandong First Medical University/Shandong Academy of Medical Sciences, Tai’an 271000,Shandong,China; 2.Department of Neurology,Tai’an First People’s Hospital,Tai’an 271000,Shandong,China)
关键词:
帕金森病; 嗅觉障碍; 1-甲基-4-苯基-1; 2; 3; 6四氢吡啶
Keywords:
Parkinson’ s disease; Olfactory dysfunction; 1-methyl-4-phenyl-1; 2; 3; 6-tetrahydropyridine
分类号:
R742.5
DOI:
10.3969/j.issn.1006-1959.2021.07.022
文献标志码:
A
摘要:
目的 探讨1-甲基-4-苯基-1,2,3,6四氢吡啶（MPTP）诱导帕金森（ PD）病小鼠嗅觉障碍的机制研究。方法 应用MPTP制备PD小鼠急性模型，腹腔注射MPTP（15 mg/kg）,每2 h注射1次，共4次，对照组注射同等剂量的生理盐水。MPTP注射后5 d，进行嗅觉功能检测，检测双侧嗅球的重量，采用Western Blot检测嗅球炎性因子环氧合酶-2（COX-2）和诱导型一氧化氮合酶（iNOS）蛋白表达。结果 注射后5 d，两组左侧和右侧嗅球重量比较，差异无统计学意义（P＞0.05）；MPTP组嗅闻旧垫料时间短于对照组，嗅闻新垫料时间长于对照组[（143.80±9.56）s vs（167.30±9.98）s]、[（156.20±9.56）s vs（131.10±10.97）s]，差异有统计学意义（P＜0.05）；MPTP组嗅球COX-2、iNOS蛋白表达高于对照组，差异有统计学意义（P＜0.05）。结论 MPTP诱导的PD小鼠急性模型能够导致小鼠嗅觉功能障碍，此作用机制可能与炎症反应有关。
Abstract:
Objective To investigate the effects of l-methyl-4-phenyl-1,2,3,6 tetrahydropyridine (MPTP) on olfactory function in Parkinson’s disease (PD) acute mouse model.Methods MPTP was used to prepare an acute model of PD in mice. MPTP (15 mg/kg) was injected intraperitoneally, once every 2 h, for a total of 4 times. The control group was injected with the same dose of normal saline.Five days after MPTP injection, the olfactory function test was performed to detect the weight of the bilateral olfactory bulbs, and Western blot was used to detect the protein expression of the inflammatory factor cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) of the olfactory bulb.Results There was no statistically significant difference in the weight of the left and right olfactory bulbs between the two groups at 5 d after injection (P>0.05);The time to smell the old litter in the MPTP group was shorter than that of the control group, and the time to smell the new litter was longer than that in the control group [(143.80±9.56)s vs (167.30±9.98)s], [(156.20±9.56)s vs (131.10±10.97)s], the difference was statistically significant (P＜0.05);The expressions of COX-2 and iNOS in the olfactory bulb of the MPTP group were both higher than those of the control group,the difference was statistically significant (P<0.05).Conclusion MPTP-induced acute PD mouse model can cause olfactory dysfunction in mice, and this mechanism of action may be related to inflammation.

参考文献/References:

[1]Michael TH.Parkinson’s Disease and Parkinsonism[J].Am J Med,2019,132(7):802-807. [2]Stephen GR,Joseph MS.Parkinson’s Disease[J].Med Clin North Am,2019,103(2):337-350. [3]Domellf ME,Lundin KF,Edstrm M,et al.Olfactory dysfunction and dementia in newly diagnosed patients with Parkinson’s disease[J].Parkinsonism&Related Disorders,2017(38):41. [4]Prashanth R,Dutta Roy S,Mandal PK,et al.Parkinson’s disease detection using olfactory loss and REM sleep disorder features[J].Annu Int Conf IEEE Eng Med Biol Soc,2014(2014):5764-5767. [5]Taekyun S,Jeongtae K,Meejung A,et al.Olfactory Dysfunction in CNS Neuroimmunological Disorders:a Review[J].Mol Neurobiol,2019,56(5):3714-3720. [6]Biju KC,Robert CE,Kripa S,et al.Methylene Blue Ameliorates Olfactory Dysfunction and Motor Deficits in a Chronic MPTP/Probenecid Mouse Model of Parkinson’s Disease[J].Neuroscience,2018(380):111-122. [7]Yang J,Lv DJ,Li LX,et al.Nicotine improved the olfactory impairment in MPTP-induced mouse model of Parkinson’s disease[J].Neurotoxicology,2019(73):175-182. [8]Chen Y,Zhang QS,Shao QH,et al.NLRP3 inflammasome pathway is involved in olfactory bulb pathological alteration induced by MPTP[J].Acta Pharmacol Sin,2019,40(8):991-998. [9] Michelle EF,James FM,John ED,et al.Olfactory Dysfunction as an Early Biomarker in Parkinson’s Disease[J].Neurosci Bull,2017,33(5):515-525. [10]Doty RL.Olfactory dysfunction in Parkinson disease[J].Nat Rev Neurol,2012,8(6):329-339. [11]Stefan S,Donato AD,Regina P,et al.Tipping Points and Endogenous Determinants of Nigrostriatal Degeneration by MPTP[J].Trends Pharmacol Sci,2017,38(6):541-555. [12]Geng J,Liu W,Gao J,et al.Andrographolide alleviates Parkinsonism in MPTP-PD mice via targeting mitochondrial fission mediated by dynamin-related protein 1[J].Br J Pharmacol,2019,176(23):4574-4591. [13]Prediger RD,Aguiar AS,Matheus FC,et al.Intranasal administration of neurotoxicants in animals:support for the olfactory vector hypothesis of Parkinson’s disease[J].Neurotox Res,2011(21):90-116. [14]Biju KC,Robert CE,Kripa S,et al.Methylene Blue Ameliorates Olfactory Dysfunction and Motor Deficits in a Chronic MPTP/Probenecid Mouse Model of Parkinson’s Disease[J].Neuroscience,2018(380):111-122. [15]Haehner A,Hummel T,Reichmann H.Olfactory loss in Parkinson’s disease[J].Parkinsons Dis,2011(2011):450939. [16]肖一峰,吴婧.帕金森病嗅觉障碍研究进展[J].中国实用神经疾病杂志,2020,23(16):1466-1472. [17]Concepció M,Dolores V,Cristóbal L,et al.Olfactory Dysfunction in Neurodegenerative Diseases[J].Curr Allergy Asthma Rep,2018,18(8):42. [18]Yuan LJ,Wang XW,Wang HT,et al.G protein-coupled estrogen receptor is involved in the neuroprotective effect of IGF-1 against MPTP/MPP+-induced dopaminergic neuronal injury[J].J Steroid Biochem Mol Biol,2019(192):105384. [19]Mohammad MK,Duraisamy K,Ramasamy T,et al.Protection of MPTP-induced neuroinflammation and neurodegeneration by Pycnogenol[J].NeurochemInt,2013,62(4):379-388. [20]Teismann P.COX-2 in the neurodegenerative process of Parkinson’s disease[J].Biofactors,2012,38(6): 395-397. [21]Cardile V,Pavone A,Gulino R,et al.Expression of brain-derived neurotrophic factor (BDNF) and inducible nitric oxide synthase (iNOS) in rat astrocyte cultures treated with Levetiracetam[J].Brain Res,2003,976(2):227-233.

相似文献/References:

[1]王姝,莫英绪,王大成.帕金森病发病因素的研究现状[J].医学信息,2018,31(01):46.[doi:10.3969/j.issn.1006-1959.2018.01.017]
　WANG Shu,MO Ying-xu,WANG Da-cheng.Research Status of the Factors of Parkinson's Disease[J].Medical Information,2018,31(07):46.[doi:10.3969/j.issn.1006-1959.2018.01.017]
[2]刘 阳,王惠凌,安 迪,等.进行性核上性麻痹1例报告[J].医学信息,2018,31(05):192.[doi:10.3969/j.issn.1006-1959.2018.05.073]
[3]陈凤全.帕金森病的诊治现状及进展[J].医学信息,2020,33(12):43.[doi:10.3969/j.issn.1006-1959.2020.12.014]
　CHEN Feng-quan.Status and Progress of Diagnosis and Treatment of Parkinson’s Disease[J].Medical Information,2020,33(07):43.[doi:10.3969/j.issn.1006-1959.2020.12.014]
[4]邓伟胜,楼云龙,苏中振.正电子发射断层扫描PET/CT在帕金森病患者早期诊断中的应用[J].医学信息,2020,33(18):170.[doi:10.3969/j.issn.1006-1959.2020.18.057]
　DENG Wei-sheng,LOU Yun-long,SU Zhong-zhen.Application of Positron Emission Tomography PET/CT in Early Diagnosis of Parkinson’s Disease[J].Medical Information,2020,33(07):170.[doi:10.3969/j.issn.1006-1959.2020.18.057]
[5]贺诗佳,孙 玲,张树山.脑内肾素-血管紧张素系统在帕金森病发病机制中的作用研究[J].医学信息,2021,34(03):34.[doi:10.3969/j.issn.1006-1959.2021.03.011]
　HE Shi-jia,SUN Ling,ZHANG Shu-shan.Study on the Role of Renin-angiotensin System in the Pathogenesis of Parkinson’s Disease[J].Medical Information,2021,34(07):34.[doi:10.3969/j.issn.1006-1959.2021.03.011]
[6]许红玉,梅育嘉,罗杰峰.神经节苷脂联合复方左旋多巴治疗帕金森病的效果[J].医学信息,2021,34(03):160.[doi:10.3969/j.issn.1006-1959.2021.03.045]
　XU Hong-yu,MEI Yu-jia,LUO Jie-feng.The Effect of Ganglioside Combined with Benserazide in the Treatment of Parkinson’s Disease[J].Medical Information,2021,34(07):160.[doi:10.3969/j.issn.1006-1959.2021.03.045]
[7]胡方婷,薛冬辉.运动-心理-睡眠护理干预对帕金森病患者负性情绪的影响[J].医学信息,2021,34(05):181.[doi:10.3969/j.issn.1006-1959.2021.05.053]
　HU Fang-ting,XUE Dong-hui.Effects of Exercise-psychological-sleep Nursing Intervention on Negative Emotions in Patients with Parkinson’s Disease[J].Medical Information,2021,34(07):181.[doi:10.3969/j.issn.1006-1959.2021.05.053]
[8]马金荣.柴胡类疏肝方药治疗帕金森病伴发抑郁患者的疗效[J].医学信息,2021,34(09):168.[doi:10.3969/j.issn.1006-1959.2021.09.045]
　MA Jin-rong.Effect of Chaihu Shugan Prescriptionon Patients with Parkinson’s Disease Complicated with Depression[J].Medical Information,2021,34(07):168.[doi:10.3969/j.issn.1006-1959.2021.09.045]
[9]蒋暐卿.单唾液酸神经节苷酯对鱼藤酮诱导的大鼠中脑神经元细胞的保护作用[J].医学信息,2021,34(10):101.[doi:10.3969/j.issn.1006-1959.2021.10.027]
　JIANG Wei-qing.Protective Effect of Monosialoganglioside on Rat Midbrain Neurons Induced by Rotenone[J].Medical Information,2021,34(07):101.[doi:10.3969/j.issn.1006-1959.2021.10.027]
[10]李贝贝,毋浪平,姚亚红.近十年国内帕金森病研究热点与趋势的可视化分析[J].医学信息,2021,34(12):15.[doi:10.3969/j.issn.1006-1959.2021.12.005]
　LI Bei-bei,WU Lang-ping,YAO Ya-hong.Visual Analysis of Domestic Parkinson’s Disease Research Hotspots and Trends in the Past Ten Years[J].Medical Information,2021,34(07):15.[doi:10.3969/j.issn.1006-1959.2021.12.005]
[11]樊 毅.帕金森病嗅觉改变的相关性研究[J].医学信息,2018,31(17):95.[doi:10.3969/j.issn.1006-1959.2018.17.029]
　FAN Yi.Correlation Study of Olfactory Changes in Parkinson's Disease[J].Medical Information,2018,31(07):95.[doi:10.3969/j.issn.1006-1959.2018.17.029]

更新日期/Last Update: 1900-01-01